Radient Pharmaceuticals Corporation fka RXPC

[dcspka]

It is highly likely PDx will continue to develop CIT at ASU. A natural fit- no ifs, ands, or butts.

Living mentioned that shares of Provista could be offered to the RXPC lenders to settle the debt. I think the agreement worked out with the lenders is already in play (31% owners of RXPC), and will come to full fruition once RXPC is resuscitated again. Do the lenders need more than the current agreement? I hope not.

I do not think that AMBS is after portions of RXPC, and will certainly not bid against PDx. AMBS is able to raise money to develop its own products at this time, but not much more. It will not go out on a limb for CIT.